Rufinamide: A double-blind, placebo-controlled proof of principle trial in patients with epilepsy

Epilepsy Research

Volumn 43, Issue 2, 2001, Pages 115-124

  Pålhagen, Sven ^a   Canger, Raffaele ^b   Henriksen, Olaf ^c   Van Parys, Johan A ^d   Rivière, Marie Emmanuelle ^e   Karolchyk, Mary Ann ^e  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b SAN PAOLO HOSPITAL   (Italy)

^c National Centre for Epilepsy   (Norway)

^d Instituut voor Epilepsiebestrijding   (Netherlands)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

AED; Antiepileptic agents; Pharmacokinetics; Rufinamide; Seizures

Indexed keywords

CARBAMAZEPINE; PHENYTOIN; PLACEBO; RUFINAMIDE; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FATIGUE; FEMALE; FOCAL EPILEPSY; GAIT DISORDER; GRAND MAL EPILEPSY; HALF LIFE TIME; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; STEADY STATE; TREMOR; VERTIGO;

ADULT; ANTICONVULSANTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HALF-LIFE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; SEIZURES; TRIAZOLES;

EID: 0035150482     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(00)00185-6     Document Type: Article

References (12)

1. Intra- and inter-subject variabilities of CGP33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension
2. ILAE report on antiepileptic drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy
3. Prototype antiepileptic drug clinical development plan
4. Efficacy and safety of rufinamide in patients with refractory epilepsy
5. Pharmacokinetic interactions between antiepileptic drugs - Clinical considerations
6. Anticonvulsant profile of CGP 33101 in animals
7. Pharmacokinetic optimization of anticonvulsant therapy
8. Gabapentin as add-on therapy in refractory partial epilepsy: A double-blind, placebo-controlled parallel-group study
9. Metabolism of the new anticonvulsive trial drug rufinamide in healthy male volunteers
10. New antiepileptic drugs
11. Clinical pharmacokinetics of valproic acid